Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis

BACKGROUND: Psoriasis is a chronic inflammatory skin disease, affecting about 0.6% of the Chinese population. Many patients are not well controlled by conventional treatments, thus there is need for new treatment regimens. In this study, we assessed the efficacy and safety of secukinumab in Chinese...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Chin Med J (Engl)
Main Authors: Cai, Lin, Zhang, Jian-Zhong, Yao, Xu, Gu, Jun, Liu, Quan-Zhong, Zheng, Min, Zhang, Shi-Fa, Xu, Jin-Hua, Li, Cheng-Xin, Cheng, Hao, Guo, Qing, Pan, Wei-Li, Li, Shen-Qiu, Li, Ruo-Yu, Guo, Zai-Pei, Song, Zhi-Qi, Li, Shan-Shan, Dong, Xiu-Qin, Wang, Linda, Fu, Rong, Regnault, Pascaline, Charef, Pascal, Mazur, Rafal, Patekar, Manmath
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7647502/
https://ncbi.nlm.nih.gov/pubmed/33060370
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CM9.0000000000001163
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados